Rybrevant
Rybrevant Redefines First-Line Care for Patients with EGFR Exon 20 Insertion Mutation (ESMO 2023)
Anika Sharma
ESMO 2023: LBA5 Targeted therapies have revolutionized the treatment of EGFR-mutant NSCLC in the last 20 years. However, EGFR exon ...
Takeda withdraw Global Lung Cancer Medication, Exkivity, Following Confirmatory Trial Failure
Anika Sharma
Following a disappointing outcome in a confirmatory trial earlier this year, Takeda has decided to discontinue its targeted non-small cell ...
J&Jās Rybrevant Beats Chemo In Lung Cancer Patients Who Failed Tagrisso
Anika Sharma
The medical community buzzed with anticipation when Johnson & Johnson (J&J) released information about Rybrevant, their latest drug venture into ...
Positive Effects of Rybrevant Plus Chemotherapy in Early EGFR Exon 20 Insertion NSCLC
SG Tylor
Source – Johnson & Johnson The combination of amivantamab-vmjw (Rybrevant) with the chemotherapy doublet carboplatin and pemetrexed has demonstrated a ...
J&Jās Rybrevant Wins in Rare Lung Cancer; Awaits Tagrisso Showdown
SG Tylor
Source – Johnson & Johnson In 2021, Johnson & Johnson’s Rybrevant received accelerated approval from the FDA, becoming the first ...
